Go Pro
→ Has Dylan Jovine lost his mind? (From Behind the Markets) (Ad)tc pixel Free CLVR Stock Alerts

Clever Leaves (CLVR) Competitors

Clever Leaves logo
$0.0002 0.00 (0.00%)
As of 09/22/2026
Compare

CLVR vs. SXTPW, BFRIW, CINGW, CMRAW, and CDTTW

Should you buy Clever Leaves stock or one of its competitors? Clever Leaves's main competitors and comparable companies include 60 Degrees Pharmaceuticals (SXTPW), Biofrontera (BFRIW), Cingulate (CINGW), Comera Life Sciences (CMRAW), and Conduit Pharmaceuticals (CDTTW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Clever Leaves compare to 60 Degrees Pharmaceuticals?

Clever Leaves (NASDAQ:CLVR) and 60 Degrees Pharmaceuticals (NASDAQ:SXTPW) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings.

60 Degrees Pharmaceuticals has lower revenue, but higher earnings than Clever Leaves.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clever Leaves$17.42M0.00-$17.90M-$9.66N/A
60 Degrees Pharmaceuticals$1.11MN/AN/AN/AN/A

In the previous week, Clever Leaves' average media sentiment score of 0.00 equaled 60 Degrees Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Clever Leaves Neutral
60 Degrees Pharmaceuticals Neutral

Company Net Margins Return on Equity Return on Assets
Clever LeavesN/A N/A N/A
60 Degrees Pharmaceuticals N/A N/A N/A

6.9% of Clever Leaves shares are owned by institutional investors. 8.2% of Clever Leaves shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Clever Leaves beats 60 Degrees Pharmaceuticals on 3 of the 3 factors compared between the two stocks.

How does Clever Leaves compare to Biofrontera?

Clever Leaves (NASDAQ:CLVR) and Biofrontera (NASDAQ:BFRIW) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership, media sentiment and risk.

In the previous week, Clever Leaves' average media sentiment score of 0.00 equaled Biofrontera'saverage media sentiment score.

Company Overall Sentiment
Clever Leaves Neutral
Biofrontera Neutral

6.9% of Clever Leaves shares are held by institutional investors. 8.2% of Clever Leaves shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Company Net Margins Return on Equity Return on Assets
Clever LeavesN/A N/A N/A
Biofrontera N/A N/A N/A

Biofrontera has higher revenue and earnings than Clever Leaves.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clever Leaves$17.42M0.00-$17.90M-$9.66N/A
Biofrontera$46.18MN/AN/AN/AN/A

Summary

Clever Leaves beats Biofrontera on 2 of the 3 factors compared between the two stocks.

How does Clever Leaves compare to Cingulate?

Clever Leaves (NASDAQ:CLVR) and Cingulate (NASDAQ:CINGW) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, media sentiment, profitability and earnings.

In the previous week, Clever Leaves' average media sentiment score of 0.00 equaled Cingulate'saverage media sentiment score.

Company Overall Sentiment
Clever Leaves Neutral
Cingulate Neutral

6.9% of Clever Leaves shares are held by institutional investors. 8.2% of Clever Leaves shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
Clever LeavesN/A N/A N/A
Cingulate N/A N/A N/A

Cingulate has lower revenue, but higher earnings than Clever Leaves.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clever Leaves$17.42M0.00-$17.90M-$9.66N/A
CingulateN/AN/AN/AN/AN/A

Summary

Clever Leaves beats Cingulate on 3 of the 3 factors compared between the two stocks.

How does Clever Leaves compare to Comera Life Sciences?

Comera Life Sciences (NASDAQ:CMRAW) and Clever Leaves (NASDAQ:CLVR) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, media sentiment, analyst recommendations, dividends and earnings.

Company Net Margins Return on Equity Return on Assets
Comera Life SciencesN/A N/A N/A
Clever Leaves N/A N/A N/A

6.9% of Clever Leaves shares are held by institutional investors. 8.2% of Clever Leaves shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Comera Life Sciences' average media sentiment score of 0.00 equaled Clever Leaves'average media sentiment score.

Company Overall Sentiment
Comera Life Sciences Neutral
Clever Leaves Neutral

Comera Life Sciences has higher earnings, but lower revenue than Clever Leaves.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Comera Life Sciences$1.00MN/AN/AN/AN/A
Clever Leaves$17.42M0.00-$17.90M-$9.66N/A

Summary

Clever Leaves beats Comera Life Sciences on 3 of the 3 factors compared between the two stocks.

How does Clever Leaves compare to Conduit Pharmaceuticals?

Clever Leaves (NASDAQ:CLVR) and Conduit Pharmaceuticals (NASDAQ:CDTTW) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

Company Net Margins Return on Equity Return on Assets
Clever LeavesN/A N/A N/A
Conduit Pharmaceuticals N/A N/A N/A

Conduit Pharmaceuticals has lower revenue, but higher earnings than Clever Leaves.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clever Leaves$17.42M0.00-$17.90M-$9.66N/A
Conduit PharmaceuticalsN/AN/AN/AN/AN/A

6.9% of Clever Leaves shares are owned by institutional investors. 8.2% of Clever Leaves shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Clever Leaves' average media sentiment score of 0.00 equaled Conduit Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Clever Leaves Neutral
Conduit Pharmaceuticals Neutral

Summary

Clever Leaves beats Conduit Pharmaceuticals on 3 of the 3 factors compared between the two stocks.

Get Clever Leaves News Delivered to You Automatically

Sign up to receive the latest news and ratings for CLVR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CLVR vs. The Competition

Export
MetricClever LeavesPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market CapN/A$12.61B$7.31B$13.28B
Dividend YieldN/A2.63%2.52%12.57%
P/E Ratio0.00792.28274.1025.70
Price / Sales0.00857.09672.6190.85
Price / CashN/A88.6477.8052.76
Price / Book0.0010.5710.486.32
Net Income-$17.90M$2.81B$3.49B$359.73M
7 Day PerformanceN/A-0.17%-0.68%0.17%
1 Month PerformanceN/A-1.39%-3.18%-3.27%
1 Year PerformanceN/A2.83%15.13%5.58%

Clever Leaves Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CLVR
Clever Leaves
N/A$0.00
flat		N/A-50.0%$0.00$17.42MN/A560
SXTPW
60 Degrees Pharmaceuticals
N/A$0.04
flat		N/A-25.4%$0.00$1.11MN/A2
BFRIW
Biofrontera
N/A$0.02
flat		N/A-80.2%$0.00$46.18MN/A70
CINGW
Cingulate
N/A$0.01
flat		N/A-85.3%$0.00N/AN/A20
CMRAW
Comera Life Sciences
N/AN/AN/AN/A$0.00$1.00MN/A2

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CLVR) was last updated on 9/24/2026 by MarketBeat.com Staff.
From Our Partners
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
While SpaceX Gets the Spotlight, FJET Is Building What Comes Next!
Starfighters Space (NYSE: FJET) operates the world's only commercial fleet of flight-ready Mach 2+ F-104 Starf...
Trading Wire | Sponsoredtc pixel
How to get a stake in Anthropic — before the IPO
Anthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...
Weiss Ratings | Sponsoredtc pixel
Why I believe the AI market will split in Q4
Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...
The Oxford Club | Sponsoredtc pixel
Congress Passes Landmark Digital Asset Law Wall Street Is Watching
The House passed the Digital Asset Market Clarity Act 294 to 134, creating the most comprehensive financial te...
Awesomely | Sponsoredtc pixel
Shocking new footage just released
Gerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...
Digest Publishing | Sponsoredtc pixel
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...
Behind the Markets | Sponsoredtc pixel
This free guide explains options the way they should be taught
Most options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...
Base Camp Trading | Sponsoredtc pixel